CAS: 139755-85-4; 5-(2-Ethoxy-5-((4-(2-Hydroxyethyl)Piperazin-1-yl)Sulfonyl)Phenyl)-1-Methyl-3-Propyl-1H-Pyrazolo[4,3-D]Pyrimidin-7(6H)-One
该化合物是一个复杂的有机化合物,其特点是多功能结构.该化学物质具有一种丙烯基核心,是一种以其生物活动为名的双循环结构.一个磺酰组和一种管状物质的存在表明与生物目标的潜在相互作用,使其对药用化学感兴趣.乙基乙基乙基亚体可能提高溶性性和生物利用率,而甲基和丙基化合物组则有助于分子的总体防水特性.该化合物有可能表现出特定的药性,有可能成为各种生物化学途径中的抑制剂或调制剂.其合成和定性将涉及标准的有机化学技术或...
- 英文名称5-(2-Ethoxy-5-((4-(2-Hydroxyethyl)Piperazin-1-yl)Sulfonyl)Phenyl)-1-Methyl-3-Propyl-1H-Pyrazolo[4,3-D]Pyrimidin-7(6H)-One
- 中文名称羟基高西地那非
- IUPAC名称5-(2-ethoxy-5-((4-(2-hydroxyethyl)piperazin-1-yl)sulfonyl)phenyl)-1-methyl-3-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one
- 其它别名Chronadalate Lp; 7H-Pyrazolo[4,3-D]Pyrimidin-7-One, 5-[2-Ethoxy-5-[[4-(2-Hydroxyethyl)-1-Piperazinyl]Sulfonyl]Phenyl]-1,6-Dihydro-1-Methyl-3-Propyl-; 1-Piperazineethanol, 4-[[3-(4,7-Dihydro-1-Methyl-7-Oxo-3-Propyl-1H-Pyrazolo[4,3-D]Pyri
- CAS编号139755-85-4
- MFCD编号:MFCD00908400
- FDA UNII编号:80X7B1F6NW
- 分子式:C23H32N6O5S分子量:504.61
- 产品CID: 616466
- 产品分类Chemistry → Organic Building Blocks → Benzene Compounds | Sulfamides | Piperazines | Amides | Other Aromatic Heterocycles | Ethers | Alcohols | Aromatic Heterocycles | Inhibitors/Agonists → Metabolic Enzyme → PDE
物理性质
上下游产品
CAS号103-76-4 N-羟乙基哌嗪 | CAS号139756-22-2 3-(6,7-dihydro-... | CAS号42926-52-3 2-乙氧基苯甲酰氯 | CAS号139756-02-8 4-氨基-1-甲基-3-正丙基... | CAS号139756-03-9 4-(2-乙氧基苯甲酰胺基)-... | CAS号139756-21-1 5-(2-乙氧苯基)-1-甲基...合成工艺路线路线简述
海关参考信息
- 2921211000-乙二胺
2922110001-单乙醇胺
2922192100-二甲氨基乙醇
2922192210-2-二乙氨基乙醇 - 💡 提示：海关信息按照顺序优先匹配，如需确认的海关信息，请参考相关资料。
- 详情请参考：📖 海关编码查询和海关进出口税则
专利信息
专利号:US-5719283-A
优先权日:1990-06-20
标 题:Intermediates useful in the synthesis of pyrazolopyrimidinone antianginal agents
发明人：BELL ANDREW SIMON; BROWN DAVID; TERRETT NICHOLAS KENNETH
权利人:PFIZER
摘要:Compounds of the formula ##STR1## wherein R 1 is H, C 1 -C 3 alkyl, C 3 -C 5 cycloalkyl or C 1 -C 3 perfluoroalkyl; n R 2 is H, C 1 -C 6 alkyl optionally substituted by OH, C 1 -C 3 alkoxy or C 3 -C 6 cycloalkyl, or C 1 -C 3 perfluoroalkyl; n R 3 is H, C 1 -C 6 alkyl, C 3 -C 6 alkenyl, C 3 -C 6 alkynyl, C 3 -C 7 cycloalkyl, C 1 -C 6 perfluoroalkyl or (C 3 -C 6 cycloalkyl)C 1 -C 6 alkyl; n and Y is chloro, bromo, or fluoro. n The above compounds are intermediates useful in the synthesis of certain pyrazolopyrimidinones which inhibit cyclic guanosine 3', 5'-monophosphate phosphodiesterase.
供应商参考报价(招募中)
品牌试剂参考报价(招募中)
📌 第三方产品分析报告
主要参考文献
1: Bacconi L, Gressier F. [Efficacy and tolerance of PDE-5 in the treatment of erectile dysfunction in schizophrenic patients: A literature review]. Encephale. 2017 Feb;43(1):55-61. doi: 10.1016/j.encep.2016.07.003. Epub 2016 Sep 19. French. doi: 10.1111/and.12557. Epub 2016 Apr 6. doi: 10.1517/14740338.2016.1131818. Epub 2016 Jan 9. Review. doi: 10.1517/14728214.2015.1021682. Epub 2015 Mar 5. Review. English, Portuguese.
6: Rubio-Aurioles E, El-Meliegy A, Abdulwahed S, Henneges C, Sorsaburu S, Gurbuz S. Decision tree analyses of key patient characteristics in Middle Eastern/North African and Latin American men treated with long-acting and short-acting PDE5 inhibitors for erectile dysfunction. Curr Med Res Opin. 2015 Feb;31(2):367-78. doi: 10.1185/03007995.2014.946125. Epub 2014 Jul 29. Erratum in: Curr Med Res Opin. 2015 Feb;31(2):378. doi: 10.1590/S1677-5538.IBJU.2014.03.14. doi: 10.1586/ecp.13.16. Review. doi: 10.3109/03639045.2013.768633. Epub 2013 Apr 24. doi: 10.1185/03007995.2013.791262. Epub 2013 Apr 16. doi: 10.1177/1756287212466282.
12: Nunes LV, Lacaz FS, Bressan RA, Nunes SO, Mari Jde J. Adjunctive treatment with lodenafil carbonate for erectile dysfunction in outpatients with schizophrenia and spectrum: a randomized, double-blind, crossover, placebo-controlled trial. J Sex Med. 2013 Apr;10(4):1136-45. doi: 10.1111/jsm.12040. Epub 2013 Jan 25. doi: 10.5414/CP201624. English, Portuguese, Spanish. doi: 10.1111/j.1743-6109.2010.01711.x. Epub 2010 Feb 25. doi: 10.1111/j.1743-6109.2008.01079.x. Epub 2008 Nov 17. doi: 10.1016/j.ejphar.2008.06.055. Epub 2008 Jun 19.
合成参考文献
参考文献:10.1016/j.bmc.2008.07.022
摘要:Antunes JE, Freitas MP, da Cunha EF, Ramalho TC, Rittner R. In silico prediction of novel phosphodiesterase type-5 inhibitors derived from Sildenafil, Vardenafil and Tadalafil. Bioorg Med Chem. 2008 Aug 15;16(16):7599–606. doi: 10.1016/j.bmc.2008.07.022.
📝 需求与反馈
尽可能描述清楚需求与问题信息
